Engineering a TACI×CD3 Bispecific Antibody to Redirect T Cells Against Multiple Myeloma - PubMed
4 hours ago
- #Multiple Myeloma
- #Immunotherapy
- #Bispecific Antibody
- A TACI×CD3 bispecific antibody was engineered to redirect T cells against multiple myeloma, showing robust T cell activation and cytotoxicity.
- It effectively targets MM cells with downregulated BCMA expression, overcoming resistance seen with BCMA-targeted therapies.
- The antibody demonstrated potent inhibition of growth in primary MM cells from patients, suggesting a promising therapeutic strategy.